Franklin Resources
SAGE

Franklin Resources’s Sage Therapeutics SAGE Stock Holding History

Franklin Resources’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,917
Closed -$1.32M – 3234
2025
Q2 		$1.32M Buy
+144,917
New +$1.07M ﹤0.01% 1872
2023
Q3 		– Sell
-301,674
Closed -$14.2M – 2767
2023
Q2 		$14.2M Sell
301,674
-49
-0% -$2.44K 0.01% 847
2023
Q1 		$12.7M Sell
301,723
-151
-0.1% -$6.49K 0.01% 877
2022
Q4 		$11.5M Sell
301,874
-159
-0.1% -$6.07K 0.01% 908
2022
Q3 		$11.8M Buy
302,033
+224
+0.1% +$8.66K 0.01% 889
2022
Q2 		$9.75M Buy
301,809
+81
+0% +$2.71K ﹤0.01% 958
2022
Q1 		$9.99M Buy
301,728
+10,148
+3% +$381K ﹤0.01% 1009
2021
Q4 		$12.4M Buy
291,580
+935
+0.3% +$39.1K ﹤0.01% 998
2021
Q3 		$12.9M Buy
290,645
+18,311
+7% +$840K ﹤0.01% 1000
2021
Q2 		$15.5M Buy
272,334
+20,949
+8% +$1.48M 0.01% 926
2021
Q1 		$18.8M Buy
251,385
+244
+0.1% +$20K 0.01% 852
2020
Q4 		$21.7M Buy
251,141
+59
+0% +$4.35K 0.01% 799
2020
Q3 		$15.3M Buy
251,082
+12,403
+5% +$629K 0.01% 828
2020
Q2 		$11.3M Hold
238,679
– – 0.01% 843
2020
Q1 		$6.86M Sell
238,679
-635,430
-73% -$36.8M ﹤0.01% 873
2019
Q4 		$63.1M Sell
874,109
-171,848
-16% -$21.1M 0.03% 492
2019
Q3 		$147M Sell
1,045,957
-1,255
-0.1% -$210K 0.08% 276
2019
Q2 		$192M Sell
1,047,212
-1,952
-0.2% -$333K 0.1% 238
2019
Q1 		$167M Buy
1,049,164
+6,209
+0.6% +$899K 0.09% 261
2018
Q4 		$99.9M Buy
1,042,955
+92,182
+10% +$10.5M 0.06% 331
2018
Q3 		$134M Buy
950,773
+379,121
+66% +$58.5M 0.07% 308
2018
Q2 		$89.5M Buy
571,652
+79,241
+16% +$12.4M 0.05% 394
2018
Q1 		$79.3M Sell
492,411
-32,179
-6% -$5.46M 0.04% 423
2017
Q4 		$86.4M Buy
524,590
+50,254
+11% +$4.87M 0.04% 409
2017
Q3 		$29.6M Sell
474,336
-34,520
-7% -$2.71M 0.01% 692
2017
Q2 		$40.5M Sell
508,856
-117,810
-19% -$8.52M 0.02% 590
2017
Q1 		$44.5M Sell
626,666
-494,737
-44% -$29M 0.02% 556
2016
Q4 		$57.3M Sell
1,121,403
-88,679
-7% -$4.18M 0.03% 486
2016
Q3 		$55.7M Sell
1,210,082
-207,895
-15% -$8.46M 0.03% 487
2016
Q2 		$42.7M Buy
1,417,977
+130,172
+10% +$4.34M 0.02% 574
2016
Q1 		$41.3M Buy
1,287,805
+93,474
+8% +$3.29M 0.02% 585
2015
Q4 		$69.6M Buy
1,194,331
+162,021
+16% +$8.03M 0.04% 456
2015
Q3 		$43.7M Buy
1,032,310
+346,900
+51% +$21.4M 0.02% 607
2015
Q2 		$50M Buy
685,410
+97,910
+17% +$6.29M 0.02% 609
2015
Q1 		$29.5M Buy
587,500
+387,500
+194% +$16.7M 0.01% 789
2014
Q4 		$7.32M Hold
200,000
– – ﹤0.01% 1110
2014
Q3 		$6.3M Buy
+200,000
New +$5.8M ﹤0.01% 1142

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Franklin Resources's SAGE Position: Q3 2025 in Review

Franklin Resources sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 144,917 shares — an estimated $1.32M sold.

Franklin Resources first reported a position in SAGE in Q3 2014 and held it in 37 quarters. The position peaked at $192M in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Franklin Resources reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Franklin Resources sold 144,917 Sage Therapeutics shares in Q3 2025, an estimated $1.32M.
  • Franklin Resources first reported a position in Sage Therapeutics in Q3 2014 and held it in 37 quarters.
  • Franklin Resources's Sage Therapeutics position peaked at $192M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.